Carlsmed, Inc. (CARL) News
Follow Carlsmed, Inc. (CARL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Carlsmed Q3 Revenue Rises 65%; Outlook and Analyst Targets Raised
EQUITY | Nov 12, 2026, 08:01 AM UTC
M
Carlsmed Shares Jump 23% After Higher Third-Quarter Revenue, Raised Guidance
Carlsmed reported third-quarter revenue above the year-earlier level and raised its 2026 revenue guidance. Shares traded 23% higher at $18.13, after reaching a session 52-week high of $18.24.
EARNINGS | Nov 11, 2026, 06:45 PM UTC
M
Carlsmed Q3 Loss Widens as Revenue Rises; Raises 2026 Outlook
Carlsmed reported a wider Q3 loss and rising revenue, and lifted its 2026 revenue outlook.
EQUITY | Nov 10, 2026, 10:33 PM UTC
M
Carlsmed Q3 Sales Jump 65%, Raises FY Revenue Guidance
EQUITY | Nov 10, 2026, 09:10 PM UTC
M
Carlsmed Reports Third-Quarter 2026 Results, Raises Full-Year Guidance
Carlsmed reported third-quarter 2026 financial results and raised its full-year guidance.
EQUITY | Nov 10, 2026, 09:01 PM UTC
L
Carlsmed launches aprevo lumbar bilateral posterior system
EQUITY | Oct 14, 2026, 01:00 PM UTC
L
Carlsmed Price Target Maintained With a $23.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 01:44 PM UTC
L
BTIG reiterates Buy rating on Carlsmed, $23 price target
BTIG reiterated their Buy rating on Carlsmed's stock with a price target of $23.00.The price target implies an upside of 52.3% from the Sep 25 close of $15.10.Key takeaways from the analyst noteStrong Growth Trajectory:
EQUITY | Sep 28, 2026, 01:33 PM UTC
L
Carlsmed Names Richard Heppenstall as CFO
By Adriano MarcheseCarlsmed has appointed Richard Heppenstall as its new chief financial officer, effective immediately.Heppenstall brings a wealth of experience to the medical technology company, having served in financ
NEWS | Sep 28, 2026, 12:59 PM UTC
H
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ: CARL ) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
LIVE | Sep 28, 2026, 12:37 PM UTC
H
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL ) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Fin
LIVE | Sep 28, 2026, 12:32 PM UTC
H
Carlsmed, Inc. (CARL) Appoints New CFO, Reaffirms FY26 Revenue Outlook
Carlsmed appointed Richard Heppenstall as CFO, succeeding Leo Greenstein, and reaffirmed FY26 revenue guidance of $74—$78M.Material DetailsContext by AI AnalystThis is a management transition with steady guidance, reinfo
EARNINGS | Sep 28, 2026, 12:32 PM UTC
L
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 GuidanceCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. NASDAQ:CARL (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized sp
NEWS | Sep 28, 2026, 12:32 PM UTC
M
Carlsmed files patent infringement suit against DeGen Medical
Carlsmed filed a patent infringement lawsuit against DeGen Medical in U.S. District Court (SC), asserting eight patents and seeking injunctive relief and damages.
EQUITY | Sep 15, 2026, 11:03 PM UTC
L
Carlsmed names Jeffrey Bertolini chief operating officer
Carlsmed appointed Jeffrey Bertolini as chief operating officer, effective September 8, 2026, according to an 8-K filing.
REGULATION | Sep 08, 2026, 08:16 PM UTC
L
Carlsmed appoints new chief operating officer
Carlsmed, Inc. announced a chief operating officer appointment.
EQUITY | Sep 08, 2026, 08:06 PM UTC
L
Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ: CARL ) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
EARNINGS | Aug 05, 2026, 08:03 PM UTC
L
CARL - Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
CARL - Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
EARNINGS | Aug 05, 2026, 08:01 PM UTC
H
US CMS Finalizes Reimbursement for Carlsmed Aprevo
CMS sets favorable reimbursement for Carlsmed procedures
REGULATION | Aug 03, 2026, 12:13 PM UTC
H
CARL: Gets Favorable Reimbursement
CARL gets favorable reimbursement for aprevo lumbar procedures
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17
Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ: CARL ) with a Buy rating and announces Price Target of $17.
EQUITY | Jul 01, 2026, 11:56 AM UTC